Clinical trials: Diabetes, Type II
Obesity, Type 2 Diabetes
Pioglitazone on Pancreatic Steatosis and Bone Health
Randomized, double blind, placebo controlled trial evaluating the effect of pioglitazone on pancreatic fat content and bone turnover markers.
- Trial name
- NCT00855010
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus, Type 2, Covid19
Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19
The COVID-19 pandemic has triggered extremely high hospitalization rates where mitigation strategies are urgently necessary to aid vulnerable Hispanic and Latino populations who are experiencing health disparities as well as high…
- Trial name
- NCT04591015
- Testing
- Hospital: DD-CA, Hospital: Usual Care (UC)
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Scripps Whittier Diabetes Institute
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
This study will investigate the efficacy and safety of BI 10773 in type 2 diabetic patients in order to provide these data for approval for BI 10773 by regulatory authorities as an antidiabetic agent as add-on therapy to…
- Trial name
- NCT01210001
- Testing
- BI 10773
- Where
- 68 sites in United States, Canada and 5 more
- Volunteers
- 499 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of JNJ-28431754 compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT00642278
- Testing
- Canagliflozin (JNJ-28431754), Sitagliptin
- Where
- 78 sites in United States, Argentina and 11 more
- Volunteers
- 451 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.
- Trial name
- NCT00849017
- Testing
- albiglutide, albiglutide uptitration
- Where
- 262 sites in United States, Mexico and 1 more
- Volunteers
- 309 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin.
- Trial name
- NCT01098539
- Testing
- albiglutide, sitagliptin
- Where
- 218 sites in United States, Australia and 13 more
- Volunteers
- 507 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.
- Trial name
- PERISCOPE (NCT00225277)
- Testing
- Pioglitazone, Glimepiride
- Where
- 79 sites in United States, Argentina and 2 more
- Volunteers
- 547 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)
A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes
- Trial name
- NCT00449930
- Testing
- sitagliptin phosphate, Comparator: metformin hydrochloride
- Volunteers
- 1,050 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Type 2
Diabetes Education With Real-time Continuous Glucose Monitoring
Determine the impact of the Compañeros en Salud (Partners in Health) curriculum in conjunction with RT-CGM on glycemic control in Latinx patients with T2D.
- Trial name
- CUTDM (NCT05394844)
- Testing
- Dexcom G6
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Washington
Type 2 Diabetes Mellitus
Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)
This study will assess the safety, tolerability, pharmacokinetics, and glucose lowering activity of MK-8245 in participants with type 2 diabetes.
- Trial name
- NCT00972322
- Testing
- MK-8245
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study of LY900014 in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 2 diabetes mellitus. The study will be conducted in participants with type 2 diabetes on insulin injection therapy to…
- Trial name
- NCT03305822
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Study of LX4211 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, and efficacy of LX4211 versus a placebo control in subjects with type 2 diabetes mellitus.
- Trial name
- NCT00962065
- Testing
- LX4211 Low Dose, LX4211 High Dose
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus Type 2 With Hyperglycemia
Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus
A 4-month, randomized, prospective, open-label comparison trial of hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses of metformin plus a sulfonylurea.
- Trial name
- NCT02303405
- Testing
- Hydroxychloroquine, Pioglitazone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Charles Drew University of Medicine and Science
Obesity and Diabetes Mellitus, Type 2
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo in severely obese Type 2 Diabetes Mellitus (T2DM) participants after 12 weeks of treatment on: the percentage change in body weight from…
- Trial name
- NCT03586830
- Testing
- JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3
- Where
- 27 sites in United States
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes
The purposes of this study are to determine: The safety of tirzepatide and any side effects that might be associated with it. How much tirzepatide gets into the bloodstream and how long it takes the body to remove it.
- Trial name
- NCT03322631
- Testing
- Tirzepatide
- Where
- 2 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
This trial is conducted in Europe. The aim of this clinical trial is to compare the change in trunk fat mass, assessed by Double Energy X-ray Absorptiometry (DEXA) after 26 weeks of treatment with insulin detemir or insulin NPH…
- Trial name
- NCT00795600
- Testing
- insulin detemir, insulin NPH
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
The OBSTACLE Hypoglycemia Study (MK-0000-158)
This study will assess the correlation between glycemic control and the hypoglycemia symptom score in patients with Type 2 diabetes, 12 weeks after addition of a sulfonylurea to an ongoing regime of oral hypoglycemic agents.
- Trial name
- NCT00907881
- Testing
- Sulfonylurea
- Volunteers
- 1,069 people
- Sponsor
- Merck Sharp & Dohme LLC
Type II Diabetes, Primary Health Care
INTEGRATE-D: A Pilot Test to Support Integration of Medical and Psychosocial Care for People With Type II Diabetes
In 2016, the American Diabetes Association (ADA) published its first-ever recommendations for integrating medical and psychosocial care for patients with Type II Diabetes Mellitus (DMII) and common mental and behavioral health…
- Conditions
- Type II Diabetes, Primary Health Care, Behavioral Health
- Trial name
- NCT04461405
- Testing
- INTEGRATE-D
- Where
- United States
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Type 2 Diabetes Mellitus
MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes).
- Trial name
- NCT00103857
- Testing
- Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Comparator: MK0431 100 mg q.d. (q.d. = once daily), Comparator: Metformin 500 mg b.i.d.
- Volunteers
- 1,208 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"
The purpose of this survey is to evaluate the long-term safety and efficacy of the alogliptin and metformin hydrochloride combination tablet in type 2 diabetes mellitus patients with renal impairment (mild), hepatic impairment…
- Trial name
- NCT03555565
- Testing
- Alogliptin and Metformin hydrochloride
- Where
- Japan
- Volunteers
- 1,026 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.